Loading...
Header Logo
Keywords
Last Name

Peter J. Miller, M.D.

TitleAssistant Professor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine - Pulmonary
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionWake Forest School of Medicine
    DepartmentInternal Medicine-Hematology and Oncology

    TitleAssistant Professor
    InstitutionWake Forest School of Medicine
    DepartmentAnesthesiology


    Collapse Biography 
    Collapse education and training
    Albany Medical Center Hospital, Albany, NY06/2011Combined Internal Medicine/Pediatrics
    Wake Forest School of Medicine/Wake Forest Baptist Health, Winston-Salem, NC06/2014Hematology
    Wake Forest School of Medicine/Wake Forest Baptist Health, Winston-Salem, NC06/2015Critical Care Medicine
    Collapse awards and honors
    2015Winston <40 Leadership Award

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bonnecaze AK, Wilson MW, Dharod A, Fletcher A, Miller PJ. Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging. Nephrology (Carlton). 2018 Oct; 23(10):921-926. PMID: 28802086.
      View in: PubMed
    2. Fernando RJ, Farmer BE, Augoustides JG, Gardner JC, Johnson SD, Ha B, Friess JO, Luedi MM, Erdoes G, Miller PJ, Ripat C, Fabbro M. Perioperative Management of Mild Hemophilia B During and After Coronary Artery Bypass Grafting: Challenges and Solutions. J Cardiothorac Vasc Anesth. 2019 02; 33(2):549-555. PMID: 30177475.
      View in: PubMed
    3. Aseem F, Zamora BG, Kauffman L, Miller PJ, John VJ. Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER. Am J Ophthalmol Case Rep. 2018 Sep; 11:72-74. PMID: 29998206.
      View in: PubMed
    4. Kuhlman P, Miller P, Farland A, Owen J, Batt K. Correlating S100B with disease course in a case of new onset, acquired thrombotic thrombocytopenic purpura (TTP): Could this be a new predictive biomarker in TTP? J Clin Apher. 2018 Aug; 33(4):541-545. PMID: 29572925.
      View in: PubMed
    5. Wilson MW, Bonnecaze AK, Dharod A, Miller PJ. Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone. South Med J. 2017 03; 110(3):217-222. PMID: 28257549.
      View in: PubMed
    6. Hunt R, Yalamanoglu A, Tumlin J, Schiller T, Baek JH, Wu A, Fogo AB, Yang H, Wong E, Miller P, Buehler PW, Kimchi-Sarfaty C. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood. 2017 02 16; 129(7):896-905. PMID: 27864296.
      View in: PubMed
    7. Bonnecaze AK, Stephens SE, Miller PJ. Non-lethal Clostridium sordellii bacteraemia in an immunocompromised patient with pleomorphic sarcoma. BMJ Case Rep. 2016 Aug 03; 2016. PMID: 27489063.
      View in: PubMed
    8. Miller PJ, Farland AM, Knovich MA, Batt KM, Owen J. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Am J Hematol. 2014 Jul; 89(7):695-7. PMID: 24668845.
      View in: PubMed
    Miller's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _